|
|
||||||||
INSERM U 317 and Laboratoire de Pharmacologie Médicale et Clinique, Faculté de Médecine, 31073 Toulouse Cedex, France
1Correspondence: INSERM U317, Laboratoire de Pharmacologie Médicale et Clinique, Faculté de Médecine, 37 Allées Jules Guesde, 31073 Toulouse Cedex, France. E-mail: galitzky{at}cict.fr
Atrial natriuretic peptide (ANP) receptors have been described on
rodent adipocytes and expression of their mRNA is found in human
adipose tissue. However, no biological effects associated with the
stimulation of these receptors have been reported in this tissue. A
putative lipolytic effect of natriuretic peptides was investigated in
human adipose tissue. On isolated fat cells, ANP and brain natriuretic
peptide (BNP) stimulated lipolysis as much as isoproterenol, a
nonselective ß-adrenergic receptor agonist, whereas C-type
natriuretic peptide (CNP) had the lowest lipolytic effect. In
situ microdialysis experiments confirmed the potent lipolytic
effect of ANP in abdominal s.c. adipose tissue of healthy subjects. A
high level of ANP binding sites was identified in human adipocytes. The
potency order defined in lipolysis (ANP > BNP > CNP) and
the ANP-induced cGMP production sustained the presence of type A
natriuretic peptide receptor in human fat cells. Activation or
inhibition of cGMP-inhibited phosphodiesterase (PDE-3B) (using insulin
and OPC 3911, respectively) did not modify ANP-induced lipolysis
whereas the isoproterenol effect was decreased or increased. Moreover,
inhibition of adenylyl cyclase activity (using a mixture of
2-adrenergic and adenosine A1 agonists receptors) did
not change ANP- but suppressed isoproterenol-induced lipolysis. The
noninvolvement of the PDE-3B was finally confirmed by measuring its
activity under ANP stimulation. Thus, we demonstrate that natriuretic
peptides are a new pathway controlling human adipose tissue lipolysis
operating via a cGMP-dependent pathway that does not involve PDE-3B
inhibition and cAMP production.Sengenès, C., Berlan, M., De
Glisezinski, I., Lafontan, M., Galitzky, J. Natriuretic peptides: a
new lipolytic pathway in human adipocytes.
Key Words: human fat cells ANP BNP lipolysis microdialysis
This article has been cited by other articles:
![]() |
N. O. Belo, M. R. Sairam, and A. M. dos Reis Impairment of the Natriuretic Peptide System in Follitropin Receptor Knockout Mice and Reversal by Estradiol: Implications for Obesity-Associated Hypertension in Menopause Endocrinology, March 1, 2008; 149(3): 1399 - 1406. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Polak, C. Moro, D. Bessiere, J. Hejnova, M. A. Marques, M. Bajzova, M. Lafontan, F. Crampes, M. Berlan, and V. Stich Acute exposure to long-chain fatty acids impairs {alpha}2-adrenergic receptor-mediated antilipolysis in human adipose tissue J. Lipid Res., October 1, 2007; 48(10): 2236 - 2246. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Moro, F. Pillard, I. de Glisezinski, F. Crampes, C. Thalamas, I. Harant, M.-A. Marques, M. Lafontan, and M. Berlan Atrial natriuretic peptide contribution to lipid mobilization and utilization during head-down bed rest in humans Am J Physiol Regulatory Integrative Comp Physiol, August 1, 2007; 293(2): R612 - R617. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Polak, C. Moro, E. Klimcakova, M. Kovacikova, M. Bajzova, M. Vitkova, Z. Kovacova, R. Sotornik, M. Berlan, N. Viguerie, et al. The atrial natriuretic peptide- and catecholamine-induced lipolysis and expression of related genes in adipose tissue in hypothyroid and hyperthyroid patients Am J Physiol Endocrinol Metab, July 1, 2007; 293(1): E246 - E251. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Gutkowska, A. Paquette, D. Wang, J.-M. Lavoie, and M. Jankowski Effect of exercise training on cardiac oxytocin and natriuretic peptide systems in ovariectomized rats Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2007; 293(1): R267 - R275. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. M. Richards Natriuretic Peptides: Update on Peptide Release, Bioactivity, and Clinical Use Hypertension, July 1, 2007; 50(1): 25 - 30. [Full Text] [PDF] |
||||
![]() |
A. Meirhaeghe, M. S. Sandhu, M. I. McCarthy, P. de Groote, D. Cottel, D. Arveiler, J. Ferrieres, C. J. Groves, A. T. Hattersley, G. A. Hitman, et al. Association between the T-381C polymorphism of the brain natriuretic peptide gene and risk of type 2 diabetes in human populations Hum. Mol. Genet., June 1, 2007; 16(11): 1343 - 1350. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Aoyagi, J.-i. Birumachi, M. Hiroyama, Y. Fujiwara, A. Sanbe, J. Yamauchi, and A. Tanoue Alteration of Glucose Homeostasis in V1a Vasopressin Receptor-Deficient Mice Endocrinology, May 1, 2007; 148(5): 2075 - 2084. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. B. McEntegart, B. Awede, M. C. Petrie, N. Sattar, F. G. Dunn, N. G. MacFarlane, and J. J.V. McMurray Increase in serum adiponectin concentration in patients with heart failure and cachexia: relationship with leptin, other cytokines, and B-type natriuretic peptide Eur. Heart J., April 2, 2007; (2007) ehm033v1. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. J. Wang, M. G. Larson, M. J. Keyes, D. Levy, E. J. Benjamin, and R. S. Vasan Association of Plasma Natriuretic Peptide Levels With Metabolic Risk Factors in Ambulatory Individuals Circulation, March 20, 2007; 115(11): 1345 - 1353. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. L. Birkenfeld, M. Boschmann, C. Moro, F. Adams, K. Heusser, J. Tank, A. Diedrich, C. Schroeder, G. Franke, M. Berlan, et al. {beta}-Adrenergic and Atrial Natriuretic Peptide Interactions on Human Cardiovascular and Metabolic Regulation J. Clin. Endocrinol. Metab., December 1, 2006; 91(12): 5069 - 5075. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Engeli, M. Boschmann, P. Frings, L. Beck, J. Janke, J. Titze, F. C. Luft, M. Heer, and J. Jordan Influence of Salt Intake on Renin-Angiotensin and Natriuretic Peptide System Genes in Human Adipose Tissue Hypertension, December 1, 2006; 48(6): 1103 - 1108. [Abstract] [Full Text] [PDF] |
||||
![]() |
I J Bujalska, M Quinkler, J W Tomlinson, C T Montague, D M Smith, and P M Stewart Expression profiling of 11{beta}-hydroxysteroid dehydrogenase type-1 and glucocorticoid-target genes in subcutaneous and omental human preadipocytes. J. Mol. Endocrinol., October 1, 2006; 37(2): 327 - 340. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. E. Malavazos, L. Morricone, A. Marocchi, F. Ermetici, B. Ambrosi, and M. M. Corsi N-terminal pro-B-type natriuretic Peptide and echocardiographic abnormalities in severely obese patients: correlation with visceral fat. Clin. Chem., June 1, 2006; 52(6): 1211 - 1213. [Full Text] [PDF] |
||||
![]() |
C. Moro, J. Polak, J. Hejnova, E. Klimcakova, F. Crampes, V. Stich, M. Lafontan, and M. Berlan Atrial natriuretic peptide stimulates lipid mobilization during repeated bouts of endurance exercise Am J Physiol Endocrinol Metab, May 1, 2006; 290(5): E864 - E869. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. R. Potter, S. Abbey-Hosch, and D. M. Dickey Natriuretic Peptides, Their Receptors, and Cyclic Guanosine Monophosphate-Dependent Signaling Functions Endocr. Rev., February 1, 2006; 27(1): 47 - 72. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Nishikimi, N. Maeda, and H. Matsuoka The role of natriuretic peptides in cardioprotection Cardiovasc Res, February 1, 2006; 69(2): 318 - 328. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Bionda, C. Bergerot, D. Ardail, C. Rodriguez-Lafrasse, and R. Rousson Plasma BNP and NT-proBNP Assays by Automated Immunoanalyzers: Analytical and Clinical Study Ann. Clin. Lab. Sci., January 1, 2006; 36(3): 299 - 306. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Lafontan, C. Moro, C. Sengenes, J. Galitzky, F. Crampes, and M. Berlan An Unsuspected Metabolic Role for Atrial Natriuretic Peptides: The Control of Lipolysis, Lipid Mobilization, and Systemic Nonesterified Fatty Acids Levels in Humans Arterioscler. Thromb. Vasc. Biol., October 1, 2005; 25(10): 2032 - 2042. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Kistorp, J. Faber, S. Galatius, F. Gustafsson, J. Frystyk, A. Flyvbjerg, and P. Hildebrandt Plasma Adiponectin, Body Mass Index, and Mortality in Patients With Chronic Heart Failure Circulation, September 20, 2005; 112(12): 1756 - 1762. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. K. Antos, S. E. Abbey-Hosch, D. R. Flora, and L. R. Potter ATP-independent Activation of Natriuretic Peptide Receptors J. Biol. Chem., July 22, 2005; 280(29): 26928 - 26932. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. L. Birkenfeld, M. Boschmann, C. Moro, F. Adams, K. Heusser, G. Franke, M. Berlan, F. C. Luft, M. Lafontan, and J. Jordan Lipid Mobilization with Physiological Atrial Natriuretic Peptide Concentrations in Humans J. Clin. Endocrinol. Metab., June 1, 2005; 90(6): 3622 - 3628. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. McCord, B. J. Mundy, M. P. Hudson, A. S. Maisel, J. E. Hollander, W. T. Abraham, P. G. Steg, T. Omland, C. W. Knudsen, K. R. Sandberg, et al. Relationship Between Obesity and B-Type Natriuretic Peptide Levels Arch Intern Med, November 8, 2004; 164(20): 2247 - 2252. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. S. Filippatos, S. D. Anker, and F. Kardaras B-type natriuretic peptide serum levels in acute heart failure Eur. Heart J., June 2, 2004; 25(12): 1085 - 1085. [Full Text] [PDF] |
||||
![]() |
G. H. Goossens, E. E. Blaak, W. H. M. Saris, and M. A. van Baak Angiotensin II-Induced Effects on Adipose and Skeletal Muscle Tissue Blood Flow and Lipolysis in Normal-Weight and Obese Subjects J. Clin. Endocrinol. Metab., June 1, 2004; 89(6): 2690 - 2696. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. R. Mehra, P. A. Uber, M. H. Park, R. L. Scott, H. O. Ventura, B. C. Harris, and E. D. Frohlich Obesity and suppressed B-type natriuretic peptide levels in heart failure J. Am. Coll. Cardiol., May 5, 2004; 43(9): 1590 - 1595. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Moro, J. Galitzky, C. Sengenes, F. Crampes, M. Lafontan, and M. Berlan Functional and Pharmacological Characterization of the Natriuretic Peptide-Dependent Lipolytic Pathway in Human Fat Cells J. Pharmacol. Exp. Ther., March 1, 2004; 308(3): 984 - 992. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. J. Wang, M. G. Larson, D. Levy, E. J. Benjamin, E. P. Leip, P. W.F. Wilson, and R. S. Vasan Impact of Obesity on Plasma Natriuretic Peptide Levels Circulation, February 10, 2004; 109(5): 594 - 600. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Sengenes, A. Bouloumie, H. Hauner, M. Berlan, R. Busse, M. Lafontan, and J. Galitzky Involvement of a cGMP-dependent Pathway in the Natriuretic Peptide-mediated Hormone-sensitive Lipase Phosphorylation in Human Adipocytes J. Biol. Chem., December 5, 2003; 278(49): 48617 - 48626. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Kuhn Structure, Regulation, and Function of Mammalian Membrane Guanylyl Cyclase Receptors, With a Focus on Guanylyl Cyclase-A Circ. Res., October 17, 2003; 93(8): 700 - 709. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Tavernier, G. Toumaniantz, M. Erfanian, M.-F. Heymann, K. Laurent, D. Langin, and C. Gauthier {beta}3-Adrenergic stimulation produces a decrease of cardiac contractility ex vivo in mice overexpressing the human {beta}3-adrenergic receptor Cardiovasc Res, August 1, 2003; 59(2): 288 - 296. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Sengenes, A. Zakaroff-Girard, A. Moulin, M. Berlan, A. Bouloumie, M. Lafontan, and J. Galitzky Natriuretic peptide-dependent lipolysis in fat cells is a primate specificity Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2002; 283(1): R257 - R265. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Holtwick, M. Gotthardt, B. Skryabin, M. Steinmetz, R. Potthast, B. Zetsche, R. E. Hammer, J. Herz, and M. Kuhn Smooth muscle-selective deletion of guanylyl cyclase-A prevents the acute but not chronic effects of ANP on blood pressure PNAS, May 14, 2002; 99(10): 7142 - 7147. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. R Kalra, S. D Anker, and A. J.S Coats Water and sodium regulation in chronic heart failure: the role of natriuretic peptides and vasopressin Cardiovasc Res, August 15, 2001; 51(3): 495 - 509. [Full Text] [PDF] |
||||
![]() |
C. Sala, B. Ambrosi, and A. Morganti Blunted Vascular and Renal Effects of Exogenous Atrial Natriuretic Peptide in Patients with Cushing's Disease J. Clin. Endocrinol. Metab., May 1, 2001; 86(5): 1957 - 1961. [Abstract] [Full Text] |
||||
![]() |
J. Galitzky, C. Sengenès, C. Thalamas, M. A. Marques, J.-M. Senard, M. Lafontan, and M. Berlan The lipid-mobilizing effect of atrial natriuretic peptide is unrelated to sympathetic nervous system activation or obesity in young men J. Lipid Res., April 1, 2001; 42(4): 536 - 544. [Abstract] [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |